Categories
Recent Posts
- XNTR-20-02 Study Update
- Xennials Therapeutics Australia Pty Ltd, in collaboration with PinotBio Inc., announces the enrollment of First patient in to the Phase 1/2 study of NTX-301 as a single agent and in combination with Standard of Care in selected solid tumors
- Xennials Therapeutics Australia Pty Ltd, in collaboration with PinotBio Inc., announces the start of a new Phase 1/2 study of NTX-301 as a single agent and in combination with Standard of Care in selected solid tumors
- Nanotechnology in Cancer Research